Table 6.
Comparisons of 30-day and 1-year outcomes between our study and others.
| Our study | CARRY29 | Asia Pacific TAVI6 | FRANCE TAVI10 | STS-ACC TVTa,17 | SURTAVI12 | |
|---|---|---|---|---|---|---|
| Time to collect TAVI data, year | 2017–2022 | 2012–2020 | 2009–2017 | 2013–2015 | 2011–2019 | 2012–2016 |
| Sample size | 90 | 1204 | 1125 | 12,804 | 276,316 | 864 |
| Mean age, year | 70.7 ± 8.8 | 73.8 ± 6.5 | 79.9 ± 8.1 | 83.4 ± 7.2 | 81 | 79.9 ± 6.2 |
| STS or Log EuroSCORE | 5.8 ± 1.0 | 6.0 | 7.1 ± 6.2 | 17.9 ± 12.3 | 5.22 | 4.4 ± 1.5 |
| Med-Eds valves, %b | 98.9–1.1 | – | 32.7–38.9 | 34.9–64.3 | – | 100.0–0.0 |
| 30-day all-cause mortality, % | 2.3 | 2.3 | 2.5 | 5.4 | 3.32 | 2.8 |
| 1-year all-cause mortality, % | 5.6 | 4.5 | 8.8 | – | 15.62 | 8.1 |
STS, Society of Thoracic Surgeons; TAVI, transcatheter aortic valve implantation.
a
Nonmissing data.
b
Med-Eds valves: CoreValve, Evolut R, Evolut Pro–Sapien, Sapien XT, Sapien 3 valves.